Clarity Pharmaceuticals Ltd. has announced updates on its SECuRE clinical trial evaluating 67Cu-SAR-bisPSMA for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Following an interim data review by the Safety Review Committee $(SRC)$, the trial will proceed with its Cohort Expansion Phase (Phase II) without modifications to the protocol. The interim results, based on data from nine participants as of November 25, 2025, indicate a favorable safety profile and promising efficacy for 67Cu-SAR-bisPSMA. Most participants in the trial were heavily pre-treated and had bone metastases. Clarity Pharmaceuticals intends to progress the product to a registrational Phase III study, with the aim of future commercialization. Results from the current phase have already been collected and assessed by the SRC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN64092) on January 15, 2026, and is solely responsible for the information contained therein.